You have free access to this content

Triosephosphate isomerase and peroxiredoxin 6, two novel serum markers for human lung squamous cell carcinoma

  1. Xiu-zhi Zhang1,2,†,
  2. Zhe-feng Xiao1,3,†,
  3. Cui Li1,
  4. Zhi-qiang Xiao1,
  5. Fang Yang1,
  6. Dan-juan Li1,
  7. Mao-yu Li1,
  8. Feng Li1,3,
  9. Zhu-chu Chen1,*

Article first published online: 14 AUG 2009

DOI: 10.1111/j.1349-7006.2009.01314.x

Issue

Cancer Science

Cancer Science

Volume 100, Issue 12, pages 2396–2401, December 2009

Additional Information

How to Cite

Zhang, X.-z., Xiao, Z.-f., Li, C., Xiao, Z.-q., Yang, F., Li, D.-j., Li, M.-y., Li, F. and Chen, Z.-c. (2009), Triosephosphate isomerase and peroxiredoxin 6, two novel serum markers for human lung squamous cell carcinoma. Cancer Science, 100: 2396–2401. doi: 10.1111/j.1349-7006.2009.01314.x

Author Information

  1. 1

    Key Laboratory of Cancer Proteomics of the Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha, Hunan

  2. 2

    Henan Medical College for Staff and Workers, Zhengzhou

  3. 3

    Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, Hunan, China

  1. †

    Xiu-zhi Zhang and Zhe-feng Xiao contributed equally to this work.

* To whom correspondence should be addressed. E-mail: tcbl@xysm.net

  • †

    Xiu-zhi Zhang and Zhe-feng Xiao contributed equally to this work.

Publication History

  1. Issue published online: 11 NOV 2009
  2. Article first published online: 14 AUG 2009
  3. (Received March 20, 2009/Revised July 18, 2009/Accepted August 6, 2009/Online publication September 7, 2009)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (279K)

There is currently substantial interest in the identification of human tumor antigens for the diagnosis and immunotherapy of cancer. In our previous study, secretion character and up-regulation of triosephosphate isomerase were observed in lung squamous cell carcinoma, and autoantibodies against triosephosphate isomerase and peroxiredoxin 6 were detected in the sera from over 25% of patients, but in none of the healthy controls. In this study, peroxiredoxin 6 was also found at higher levels in the sera of the patients. Up-regulated triosephosphate isomerase and peroxiredoxin 6 were further validated by enzyme-linked immunosorbent assay in an additional 61 lung squamous cell carcinoma patients, 23 lung adenocarcinoma patients, 56 other types of carcinoma patients, 12 benign lung disease patients, and 59 healthy controls. We found that both triosephosphate isomerase and peroxiredoxin 6 were specifically elevated in lung squamous cell carcinoma sera compared with other groups, with the exception of peroxiredoxin 6 in lung adenocarcinoma patients. Positive correlation between triosephosphate isomerase and distant metastasis was found. At the cut-off point 0.221 (optical density value) on the receiver operating characteristic curve, triosephosphate isomerase could comparatively discriminate lung squamous cell carcinoma from healthy controls with a sensitivity of 65.6%, specificity 84.7%, and total accuracy 75%. For peroxiredoxin 6, at the cut-off point 0.151, it could discriminate the two groups with a sensitivity of 70.5%, specificity 62.7%, and total accuracy 65.8%. With both triosephosphate isomerase and peroxiredoxin 6, discriminant analysis results showed that 68.9% of the lung squamous cell carcinoma and 83.1% of healthy controls were correctly classified. We concluded that triosephosphate isomerase and peroxiredoxin 6 could be markers for lung squamous cell carcinoma. (Cancer Sci 2009; 100: 2396–2401)

View Full Article (HTML) Get PDF (279K)